BigStock Images The U.S. Food and Drug Administration (FDA) has approved NUMELVI (atinvicitinib tablets), a second-generation Janus kinase (JAK) inhibitor developed by Merck Animal Health for the control of pruritus associated with allergic dermatitis in dogs six months of age and older. The once-daily oral medication inhibits JAK1-dependent cytokines involved in itch and inflammation. According to the manufacturer, the drug “offers added convenience for veterinary clinics; most dogs, starting at weights as low as 4.4 pounds, require only one or half of a tablet, and there is no need to adjust vaccination schedules.” NUMELVI is reported to become available in the U.S. in spring 2026. For more information, visit the Merck Animal Health website.
